Giselle de Barros Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giselle de Barros Silva has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aline Donati
Department of Dermatology, University of São Paulo, São Paulo, Brazil
3 shared publications - Corina J. G. van Den Hurk
Department of Research and Development (C.J.G.H., N.J.H.R., H.P.F.), Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands; Santeon (C.J.G.H.), Utrecht, The Netherlands; Catharina Hospital (C.J.G.H.), Eindhoven, The Netherlands
3 shared publications - Kathryn Ciccolini
Department of Hematology/Oncology, Mount Sinai Hospital, New York, NY, United States of America
3 shared publications - Adriana Pessoa Mendes Eris
Dermatology Clinic, Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil; Skin Cancer Unit, A.C. Camargo Cancer Center, São Paulo, SP, Brazil
2 shared publications - Cristina Martinez Zugaib Abdalla
Department of Dermatology, Hospital Sírio Libanês, São Paulo, SP, Brazil
2 shared publications - Jade Cury-Martins
Department of Dermatology University of São Paulo Medical School Sao Paulo Brazil
2 shared publications
Latest Publications
- 24 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (9) , e794-e795
Hair repigmentation in Sézary syndrome
- 24 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (9) , e794-e795
Hair repigmentation in Sézary syndrome
- 29 August 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (1) , E99-E101
Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm
- 29 August 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (1) , E99-E101
Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm
- Open Access
- 1 September 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 95 (5) , 631-637
Scalp cooling to prevent chemotherapy-induced alopecia
- 1 September 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 95 (5) , 631-637
Open AccessScalp cooling to prevent chemotherapy-induced alopecia
- Open Access
- 1 September 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 95 (5) , 631-637
Resfriamento do couro cabeludo na prevenção da alopecia induzida por quimioterapia: visão geral
- 1 September 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 95 (5) , 631-637
Open AccessResfriamento do couro cabeludo na prevenção da alopecia induzida por quimioterapia: visão geral
- Open Access
- 1 September 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 95 (5) , 631-637
Scalp cooling to prevent chemotherapy-induced alopecia
- 1 September 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 95 (5) , 631-637
Open AccessScalp cooling to prevent chemotherapy-induced alopecia
- Open Access
- 1 March 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 95 (2) , 221-237
Manejo dos eventos adversos dermatológicos das terapias oncológicas: recomendações de um painel de especialistas
- 1 March 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 95 (2) , 221-237
Open AccessManejo dos eventos adversos dermatológicos das terapias oncológicas: recomendações de um painel de especialistas
- Open Access
- 1 March 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 95 (2) , 221-237
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel
- 1 March 2020
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 95 (2) , 221-237
Open AccessManagement of dermatologic adverse events from cancer therapies: recommendations of an expert panel
- Open Access
- 1 June 2015
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 90 (3 suppl 1) , 242-246
Vemurafenib and cutaneous adverse events - report of five cases
Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.
- 1 June 2015
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 90 (3 suppl 1) , 242-246
Open AccessVemurafenib and cutaneous adverse events - report of five cases
Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.